CA3214088A1 - Pkc-theta modulators - Google Patents

Pkc-theta modulators Download PDF

Info

Publication number
CA3214088A1
CA3214088A1 CA3214088A CA3214088A CA3214088A1 CA 3214088 A1 CA3214088 A1 CA 3214088A1 CA 3214088 A CA3214088 A CA 3214088A CA 3214088 A CA3214088 A CA 3214088A CA 3214088 A1 CA3214088 A1 CA 3214088A1
Authority
CA
Canada
Prior art keywords
group
alkyl
hydrogen
mmol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214088A
Other languages
English (en)
French (fr)
Inventor
Peter Ray
Anthony Bradley
Simon Richards
Catarina SANTOS
Jeremy Besnard
Jerome Meneyrol
Virginie SUCHAUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Exscientia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exscientia Ltd filed Critical Exscientia Ltd
Publication of CA3214088A1 publication Critical patent/CA3214088A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)
CA3214088A 2021-05-06 2022-05-06 Pkc-theta modulators Pending CA3214088A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2106486.0 2021-05-06
GB202106486 2021-05-06
PCT/GB2022/051167 WO2022234299A1 (en) 2021-05-06 2022-05-06 Pkc-theta modulators

Publications (1)

Publication Number Publication Date
CA3214088A1 true CA3214088A1 (en) 2022-11-10

Family

ID=82100804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214088A Pending CA3214088A1 (en) 2021-05-06 2022-05-06 Pkc-theta modulators

Country Status (14)

Country Link
US (1) US20240239794A1 (cg-RX-API-DMAC7.html)
EP (1) EP4334316A1 (cg-RX-API-DMAC7.html)
JP (1) JP7874663B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240024063A (cg-RX-API-DMAC7.html)
CN (1) CN117295738A (cg-RX-API-DMAC7.html)
AU (1) AU2022269348A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022883A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214088A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003247A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015005A2 (cg-RX-API-DMAC7.html)
IL (1) IL307669A (cg-RX-API-DMAC7.html)
MX (1) MX2023013012A (cg-RX-API-DMAC7.html)
PE (1) PE20250019A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022234299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240262821A1 (en) * 2021-05-06 2024-08-08 Exscientia Al Limited PKC-Theta Modulators
CN118772140B (zh) * 2023-04-07 2026-04-17 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途
WO2025255294A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use
WO2025255298A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173635B2 (en) * 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors
GB0920382D0 (en) 2009-11-20 2010-01-06 Univ Dundee Design of molecules
AU2010352577A1 (en) * 2010-05-05 2012-01-19 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors
RU2016129380A (ru) 2013-12-20 2018-01-25 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием
EP3976612A4 (en) * 2019-05-28 2023-04-26 Mankind Pharma Ltd NEW COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
US20240262821A1 (en) * 2021-05-06 2024-08-08 Exscientia Al Limited PKC-Theta Modulators

Also Published As

Publication number Publication date
WO2022234299A1 (en) 2022-11-10
JP2024518447A (ja) 2024-05-01
AU2022269348A1 (en) 2023-10-26
CO2023015005A2 (es) 2024-02-05
US20240239794A1 (en) 2024-07-18
EP4334316A1 (en) 2024-03-13
MX2023013012A (es) 2024-03-25
IL307669A (en) 2023-12-01
JP7874663B2 (ja) 2026-06-16
PE20250019A1 (es) 2025-01-07
KR20240024063A (ko) 2024-02-23
BR112023022883A2 (pt) 2024-01-23
CN117295738A (zh) 2023-12-26
CL2023003247A1 (es) 2024-04-26

Similar Documents

Publication Publication Date Title
US20260109698A1 (en) Malt-1 modulators
CN111153901A (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
CN116981675A (zh) 通过布鲁顿氏酪氨酸激酶(btk)抑制剂与e3连接酶配体的缀合降解btk和使用方法
CA3047212A1 (en) Tyrosine amide derivatives as rho- kinase inhibitors
CA3213703A1 (en) Pkc-theta modulators
US20240239794A1 (en) PKC-Theta Modulators
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
TW202315870A (zh) 布魯頓氏酪胺酸激酶之抑制劑
EP3668877B1 (en) Indole derivatives as histone demethylase inhibitors
TW202428267A (zh) 用於降解egfr激酶之化合物
TW202330537A (zh) Wee1抑制劑及其製備和用途
TW202340198A (zh) 靶向malt1的蛋白降解化合物、包含其的醫藥組合物及其用途
JP2026502207A (ja) 硫黄/酸素置換グルタルイミジルイミドイソインドリノン骨格に基づいた化合物及びその応用
WO2023183437A1 (en) Tead inhibitors and methods of use
CA3256816A1 (en) LRRK2 INHIBITORS
EP4393919A1 (en) Lsd1 modulators
EA046667B1 (ru) ПИРРОЛО[2,3-b]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРА HPK1 И ИХ ПРИМЕНЕНИЕ
KR20260019509A (ko) Gpr68 조절 활성을 갖는 이환식 헤테로아릴아미드
CN121464138A (zh) Mllt1和/或mllt3的protac降解剂
CA3159250A1 (en) New compounds for treatment of diseases related to dux4 expression

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260420

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260421

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260428

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260428

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260428

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260428

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428